pro-NT & CVD prediction in women
- Elevated fasting plasma levels of pro-NT are associated with increased risk of cardiovascular diseases in women3,4
- pro-NT release is stimulated by the uptake of fatty acids
- Cardiovascular disease risk can be monitored by sphingotest® pro-NT and influenced by diet and life-style adjustments
vr-hGH & CVD prediction in men
- High plasma levels of Human Growth Hormone hGH are associated with cardiovascular disease and mortality5
- sphingotest® vr-hGH is an ultra sensitive immunoassay for hGH, indicating the vascular risk in men
- Prediction of cardiovascular risk in men (Hazard Ratio greater than 15) for guidance of cardiovascular check-up
- Prevention of disease: Identified risk can be counteracted with ACEi/ARB therapy – independent of blood pressure
sphingotest® pro-NT Immunoassay
- sphingotest® pro-NT utilizes a stable fragment of the Neurotensin precursor molecule (Proneurotensin) that is produced in the same ratio as Neurotensin
- The sphingotest® pro-NT Broschure can be downloaded here
sphingotest® vr-hGH Immunoassay
- sphingotest® vr-hGH is an ultra sensitive assay for Human Groth Hormone (hGH), indicating the vascular risk in men
- The only IVD method to determine the low fasting plasma levels in men
- The sphingotest® vr-hGH Broschure can be downloaded here
- WHO Fact Sheet: Cardiovascular Diseases (CVDs)
- Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, Jonsson B, Schenck-Gustafsson K, Tendera M. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J. 2006; 27(8):994-1005. PubMed PMID: 16522654.
- Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, Engström G, Kilger U, Nilsson P, Bergmann A, Orho-Melander M. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012; 308(14):1469-75. PubMed PMID:23047361.
- Fawad A, Schultz C, Nilsson PM, Orho-Melander M, Melander O. 1C.07: Proneurotensin independently precdicts cardiovascular disease. The Malmö Preventive Project. J Hypertens. 2015; 33 Suppl 1:e11. PubMed PMID: 26102676.
- Hallengren E, Almgren P, Engström G, Hedblad B, Persson M, Suhr J, Bergmann A, Melander O. Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmö Diet and Cancer study. J Am Coll Cardiol. 2014; 64(14):1452-60. PubMed PMID: 25277616